2012 ONKOLOGIE

ACTA MEDICINAE 2/2012 ONKOLOGIE Kompletní literatura 2

Informační zázemí onkologických screeningových programů ČR a jejich výsledky hodnocené z mezinárodního hlediska

2

Chemoterapie a hormonální léčba karcinomu prsu

3

Prevence nevolnosti a zvracení po chemoterapii

4

Novinky v léčbě karcinomu prsu

5

Projekt 35 – příliš mladá na karcinom prsu?

5

Nejnovější poznatky v léčbě pokročilého hepatocelulárního karcinomu

5

Biologická léčba nádorů ledvin

6

Karcinom plic

7

Komplexní léčba metastatického kolorektálního karcinomu

7

Karcinom žaludku

7

Germinální nádory varlat – přehled diagnostiky a terapie

8

Současné možnosti léčby karcinomu slinivky břišní

9

Výživa onkologického pacienta

9

Současné možnosti léčby průlomové bolesti onkologických pacientů

10

Léčba olanzapinem u pacientů se schizofrenií

10

Depresivní porucha a její léčba

11

Role mikroRNA při vzniku nádorů a možnosti jejich využití v léčbě

kolektiv autorů

MUDr. Katarína Petráková Klinika komplexní onkologické péče MOU, Brno doc. MUDr. Miroslav Tomíška, CSc. Interní hematologická a onkologická klinika LF MU a FN, Brno MUDr. Michal Vočka | MUDr. Zuzana Ušiaková | prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika 1. LF UK a VFN a ÚVN, Praha doc. MUDr. Petra Tesařová, DrSc. Onkologická klinika 1. LF UK a VFN, Praha prof. MUDr. Jitka Abrahámová, DrSc. Onkologická klinika 1. LF UK a Thomayerovy nemocnice s poliklinikou, KOC (NNB, VFN a TN), Praha

doc. MUDr. Jindřich Fínek, Ph.D. Onkologické a radioterapeutické oddělení FN a LF UK, Plzeň MUDr. Bohdan Kadlec | prof. MUDr. Jana Skřičková, CSc. | MUDr. Marcela Tomíšková Klinika nemocí plicních a tuberkulózy LF MU a FN, Brno MUDr. Igor Kiss, Ph.D. | MUDr. Jana Halámková Klinika komplexní onkologické péče MOU a LF, Brno

MUDr. Jiří Tomášek Klinika komplexní onkologické péče MOU, Brno MUDr. Tomáš Büchler, Ph.D. | prof. MUDr. Jitka Abrahámová, DrSc. Onkologická klinika Fakultní Thomayerovy nemocnice s poliklinikou a 1. LF UK, Praha MUDr. Michal Vočka | prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika 1. LF UK a VFN a ÚVN, Praha

doc. MUDr. Miroslav Tomíška, CSc. Interní hematologická a onkologická klinika LF MU a FN, Brno MUDr. Ondřej Sláma, Ph.D. Ambulance podpůrné a paliativní onkologie, Klinika komplexní onkologické péče MOU, Brno

doc. MUDr. Klára Látalová, Ph.D. Klinika psychiatrie FN Olomouc, LF UP, Olomouc prof. MUDr. Ján Praško, CSc. | doc. MUDr. Klára Látalová, Ph.D. Klinika psychiatrie FN Olomouc, LF UP, Olomouc prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha

Informační zázemí onkologických screeningových programů ČR a jejich výsledky hodnocené z mezinárodního hlediska kolektiv autorů 1 Prorok, P. – Kramer, B. – Gohagan, J.: Screening Theory and Study Design: The Basics. In: Kramer, B. – Gohagan, J. – Prorok, P. (eds.): Cancer Screening – Theory and Practise. New York, Marcel Dekker, 1999. 2 Rada Evropské unie: Doporučení rady ze dne 2. prosince 2003 o screeningu zhoubných nádorů. On-line ec.europa.eu/health/ph_information/ dissemination/diseases/docs/cancer_recommendation_cs.pdf, cit. 20. 8. 2008. 3 Arbyn, M. – Anttila, A. – Jordan, J. – Ronco, G. – Schenck, U. – Segnan N., et al.: European guidelines for quality assurance in cervical can cer screening, 2nd ed. Luxembourg, European Communities, 2008. 4 Perry, N. – Broeders, M. – de Wolf, C. – Tornberg, S. – Holland, R. – von Karsa, L., et al. (eds.): European guidelines for quality assurance in breast cancer screening and diagnosis, 4th ed. Luxembourg, Office for Official Publications of the EC, 2006. 5 Segnan, N. – Patnick, J. – von Karsa, L. (eds.): European guidelines for quality assurance in colorectal cancer screening and diagnosis. Luxembourg, Publications Office of the European Union, 2010. 6 Dušek, L. – Mužík, J. – Kubásek, M. – Koptíková, J. – Žaloudík, J. – Vyzula, R.: Epidemiologie zhoubných nádorů v České republice. On-line http://www.svod.cz. 2007, cit. 2009. 7 Dušek, L. – Mužík, J. – Kubásek, M. – Koptíková, J. – Žaloudík, J. – Vyzula, R.: Epidemiologie zhoubných nádorů v České republice. 2005, www.svod.cz, cit. 14. 9. 2009. 8 Pavlík, T. – Dušek, L. – Májek, O. – Žaloudík, J.: Five-Year Survival Rates of Cancer Patients in the Czech Republic. In: Dušek, L., et al. (eds.): Czech Cancer Care in Numbers 2008–2009. Praha, Grada Publi shing, 2009. 9 Pavlik, T. – Majek, O. – Muzik, J. – Koptikova, J. – Slavicek, L. – Finek, J., et al.: Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry. BMC Public Health, 2012, 12 (1), s. 117. 10 Nystrom, L. – Andersson, I. – Bjurstam, N. – Frisell, J. – Nordenskjold, B. – Rutqvist, L. E.: Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet, 2002, 359 (9310), s. 909–919. 11 Mandel, J. S. – Bond, J. H. – Church, T. R. – Snover, D. C. – Bradley, G. M. – Schuman, L. M., et al.: Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med, 1993, 328 (19), s. 1365–1371. 12 Hakama, M. – Rasanen-Virtanen, U.: Effect of a mass screening

program on the risk of cervical cancer. Am J Epidemiol. 1976, 103 (5), s. 512–517. 13 Day, N. – Williams, D. – Khaw, K.: Breast cancer screening programmes: the development of a monitoring and evaluation system. Br J Cancer, 1989, s. 954–958. 14 Lieberman, D. – Nadel, M. – Smith, R. A. – Atkin, W. – Duggirala, S. B. – Fletcher, R., et al.: Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. Gastrointest Endosc, 2007, 65 (6), s. 757–766. 15 Vainio, H. – Bianchini, F. (eds.): Breast Cancer Screening. Lyon, IARCPress, 2002. 16 Althuis, M. D. – Dozier, J. M. – Anderson, W. F. – Devesa, S. S. – Brinton, L. A.: Global trends in breast cancer incidence and mortality 1973–1997. Int J Epidemiol, 2005, 34 (2), s. 405–412. 17 Brenner, H. – Gondos, A. – Arndt, V.: Recent major progress in longterm cancer patient survival disclosed by modeled period analysis. J Clin Oncol, 2007, 25 (22), s. 3274–3280. 18 de Vries, E. – Karim-Kos, H. E. – Janssen-Heijnen, M. L. – Soerjomataram, I. – Kiemeney, L. A. – Coebergh, J. W.: Explanations for worsening cancer survival. Nat Rev Clin Oncol, 2010, 7 (1), s. 60–63. 19 Karsa, L. – Anttila, A. – Ronco, G. – Ponti, A. – Malila, N. – Arbyn, M., et al.: Cancer Screening in the European Union: Report on the implementa tion of the Council Recommendation on cancer screening. Luxembourg, European Communities, 2008. 20 Zavoral, M. – Suchanek, S. – Zavada, F. – Dusek, L. – Muzik, J. – Sei fert, B., et al.: Colorectal cancer screening in Europe. World J Gastro enterol, 2009, 15 (47), s. 5907–5915. 21 Majek, O. – Danes, J. – Skovajsova, M. – Bartonkova, H. – Buresova, L. – Klimes, D., et al.: Breast cancer screening in the Czech Republic: time trends in performance indicators during the first seven years of the organised programme. BMC Public Health, 2011, 11, s. 288. 22 Mansmann, U. – Crispin, A. – Henschel, V. – Adrion, C. – Augustin, V. – Birkner, B., et al.: Epidemiology and quality control of 245 000 outpatient colonoscopies. Dtsch Arztebl Int, 2008, 105 (24), s. 434–440. 23 Kaminski, M. F. – Regula, J. – Kraszewska, E. – Polkowski, M. – Wojciechowska, U. – Didkowska, J., et al.: Quality indicators for colo noscopy and the risk of interval cancer. N Engl J Med, 2010, 362 (19), s. 1795–1803.

Chemoterapie a hormonální léčba karcinomu prsu MUDr. Katarína Petráková Klinika komplexní onkologické péče MOU, Brno 1 Kaufmann, M. – von Minckwitz, G. – Bear, H. D., et al.: Recommendation from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol, 2007, 18 (12), s. 1927–1934. 2 Ring, A. E. – Smith, I. E. – Ashley, S., et al.: Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer, 2004, 91, s. 2012–2017. 3 Goldhirsch, A. – Wood, W. C. – Gelber, R. D., et al.: Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol, 2011, 22 (8), s. 1736–1747.

4 Fischer, B. – Neony, J. H. – Bryant, J., et al.: Treatment of lymphnode-negative, oestrogen receptor positive breast cancer:long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet, 2004, 364, s. 858–868. 5 Albain, K. – Barlow, W. – O´Malley, F., et al.: Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamid, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesteron (PgR) receptor-positive breast cancer: mature outcomes and new biological correlates on phase III intergroup trial 0100 (SWOG.-8814). Breast Cancer Res Treat, 2004, 88 (dopl. 1), abs. 37. 6 Henderson, I. C. – Berry, D. A. – Demetri, G. D., et al.: Improved

ACTA MEDICINAE 2/2012 ONKOLOGIE Kompletní literatura

outcomes from adding sequential paclitaxel, but not from escalating doxorubicin dose in an adjuvant chemotherapy regiment for patiens with node positive primary breast cancer. J Clin Oncol, 2003, 21, s. 976–983. 7 Roche, H. – Fumoleau, P. – Spielman, M., et al.: Sequential adjutant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients:the FNCLCC PACS 01 Trial. J Clin Oncol, 2006, 24 (36), s. 5664–5671. 8 Francis, P. – Crown, J. – Di Leo, A., et al.: BIG 02-98 Collaborative Group. Adjutant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst, 2008, 100 (2), s. 121–133. 9 Martin, M. – Pienkowski, T. – Mackey, J., et al.: Breast Cancer International Researche Group 001 Investigators. Adjutant docetaxel for node-positive breast cancer. N Engl J Med, 2005, 352 (22), s. 2302–2313. 10 Jones, et al.: Breast Cancer Res Treat, 2007, 106 (dopl. 1), s. S5, abs. 12. 11 Cuzik, J. – Ambroisine, L. – Davidson, N., et al.: Use of luteinising-hor mone-realising hormone agonists as adjuvant treatment in preme nopausal patiens with hormone-receptor-positive breast cancer: a metaanalysis of individual patient data from randomised adjuvant trials. Lancet, 2007, 369, s. 1711–1723. 12 Peto, R. – Davies, C., and the ATLAS investigators: ATLAS (Adjutant Tamoxifen Longer Against Shorter):international randomised trial of 10 vs 5 years of adjutant tamoxifen among 11,500 women: prelimina ry results. Breast Cancer Res Treat, 2007, 106 (dopl. 1), s. S00, abs. 48. 13 Rea, D. W. – Hanley, K. – Marshall, M., et al.: aTTom (adjutant Tamoxi fen-To offer more?): Randomised trial of 10 versus 5 years of adjutant tamoxifen among 6,934 women with estrogen receptor positive (ER+) or ER untested breast cancer- Preliminary results. Proc Am Soc Clin Oncol, 2 008, abs. 513. 14 Forbes, J. F. – Cuzick, J. – Buzdar, A., et al.: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol, 2008, 9, s. 45–53. 15 Coates, A. S. – Kashaviah, A. – Thurlimann, B., et al.: Five years of le trozole compared with tamoxifen as initial adjutant therapy for post menopausal women with endocrine-responsive early breast cencer: update of study BIG 1-98. J Clin Oncol, 207, 25, s. 486–492. 16 Goss, P. E. – Unyle, J. N. – Martino, S., et al.: Randomized trial of letrozole following tamoxifen as extended adjutant therapy in

receptor-positive breast cancer: update findings from NIC CTG MA17. J Natl Cancer Indy, 2005, 97, s. 1262–1271. 17 Carrick, S. – Parker, S. – Wilcken, N., et al.: Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Databáze Syst Rev, 2005, 2, Art No. CD003372, doi: 10.1002/14651858. 18 Bruzzi, P. – Del Mastro, L. – Formani, M. P., et al.: Objective response to chemotherapy as a potential surrogate and point of survival in metastatic breast cancer patiens. J Clin Oncol, 2005, 23, s. 5117–5125. 19 Greenberg, P. A. – Hortobagyi, G. N. – Smith, T. L., et al.: Long-term follow-up of patiens with complete remission following combina tion chemotherapy for metastatic breast cancer. J Clin Oncol, 1996, 14, s. 2197–2205. 20 Nabholtz, J. M. – Falkon, C. – Campos, D., et al.: Docetaxel and do xorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer:results of a rando mized, multicenter, phase III. trial. J Clin Oncol, 2003, 21, s. 968–975. 21 Jassem, J. – Pienkowski, T. – Pluzanska, A., et al.: Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with metastatic breast cancer:final re sults of a randomised phase III multicenter trial. J Clin Oncol, 2001, 19, s. 1707–1715. 22 Boneneterre, J. – Thurlimann, B. – Robertson, J. F., et al.: Anastrozol versus tamoxifen in first-line therapy for advanced breast cancer in 668 postmenopausal women:results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol, 200, 18, s. 3748–3757. 23 Nabholtz, J. M. – Buzdar, A. – Pollak, M., et al.: Anastrozol is superior to tamoxifen as first-line therapy for advanced breast cancer in postme nopausal women:results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol, 2000, 18, s. 3758–3767. 24 Howell, A. – Robertson, J. F. – Abram, P., et al.: Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomised trial. J Clin Oncol, 2004, 22, s. 1605–1613. 25 Klijn, J. G. – Blamey, R. W. – Boccardo, F., et al.: Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomised trials. J Clin Oncol, 2001, 19, s. 343–353.

Prevence nevolnosti a zvracení po chemoterapii doc. MUDr. Miroslav Tomíška, CSc. Interní hematologická a onkologická klinika LF MU a FN, Brno 1 Grunberg, S. – Deuson, R. R. – Mavros, P., et al.: Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Can cer, 2004, 100, s. 2261–2268. 2 Roila, F. – Herrstedt, J. – Aapro, M., et al.: Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus confe rence. Ann Oncol, 2010, 21 (dopl. 5), s. v232–v243. 3 Ettinger, D. S., and Pannel Members: NCCN Clinical Practice Guidelines in Oncology. Version I.2012. //www.nccn.org/professionals/physician_gls/ . 4 Ellebaek, E. – Herrstedt, J.: Optimizing antiemetic therapy in multipleday and multiple cycles of chemotherapy. Current Opinion in Suppor tive and Palliative Care, 2008, 2, s. 28–34. 5 Schwartzberg, L. – Szabo, S. – Gilmore, J., et al.: Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately and highly emetogenic chemotherapy (LEC, MEC, HEC). Curr Med Res Opinion, 2011, 27, s. 837–845. 6 Hesketh, P. J. – Aapro, M. – Street, J. C. – Carides, A. D.: Evaluation of risk factors predictive of nausea and vomiting with current standard-

-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer, 2010, 18 (9), s. 1171–1177. 7 Warr, D. G. – Street, J. C. – Carides, A. D.: Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Sup port Care Cancer, 2011, 19 (6), s. 807–813. 8 Rojas, C. – Thomas, A. G. – Alt, J., et al.: Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. European J Pharmacol, 2010, 626, s. 193–199. 9 Navari, R. M.: Prevention of emesis from multiple-day and high-dose chemotherapy regimens. J Nation Compr Cancer Network, 2007, 5, s. 51–59. 10 Warr, D. G. – Grunberg, S. M. – Gralla, R. J. – Hesketh, P. J. – Roila, F. – deWit, R., et al.: The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled


trials. E ur J Cancer, 2005, 41, s. 1278–1285. 11 Botrel, T. E. – Clark, O. A. – Clark, L., et al.: Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care in Cancer, 2011, 19, s. 823–832. 12 Rapoport, B. L. – Jordan, K. – Boice, J. A., et al.: Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated

with broad spectrum of moderately emetogenic chemotherapies and tumor types: a randomized, double blind study. Support Care Cancer, 2009, doi: 10.1007/s00520-009-0680-9. 13 Grunberg, S. – Clark-Snow, R. A. – Koeller, J.: Chemotherapy-induced nausea and vomiting: contemporary approaches to optimal management. Support Care Cancer, 2010, 18 (dopl. 1), s. S1–S10. 14 Bash, E. – Prestrud, A. A. – Hesketh, P. J. – Kris, M. G., et al.: Antieme tics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol, 2011, doi: 10.1200/JCO.2010.34.4614.

Novinky v léčbě karcinomu prsu MUDr. Michal Vočka | MUDr. Zuzana Ušiaková | prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika 1. LF UK a VFN a ÚVN, Praha 1 Petruželka, L.: Současné možnosti a nové perspektivy systémové léčby karcinomu prsu. Klin Farmakol Farm, 21, 2007, s. 11–17. 2 Petruželka, L.: Karcinom prsu – jak dál v diagnostice a léčbě ve světle nových možností. Vnitř Lék, 53, 2007, s. 22–23. 3 Petruželka, L.: Nové možnosti léčby ErbB2 a hormonálně dependentních karcinomů prsu. Klin. Farmakoter, 2012, v tisku. 4 Higgins, M. J. – José Baselga, J.: Targeted therapies for breast cancer. J Clin Invest, 2011, 121 (10), s. 3797–3803. 5 Tang, R. Y. – Finn, R. S.: Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. British Journal of Cancer, 2012, 106, s. 6–13. 6 Slamon, D. J. – Leyland-Jones, B. – Shak, S., et al.: Use of chemothe rapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344, 2001, s. 783–790. 7 Pegram, M. D. – Konecny, G. E. – O’Callaghan, C., et al.: Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst, 2004, 96, s. 739–745. 8 Petruželka, L.: Biologická léčba karcinomu prsu. Onkologie, 3, 2009, s. 19–27. 9 Baselga, J. – Cortés, J. – Kim, S.-B., et al.: Pertuzumab plus trastuzu mab plus docetaxel for metastatic breast cancer. N Engl J Med, 2011, 366 (2), s. 109–119. 10 Lewis Phillips, G. D. – Li, G. – Dugger, D. L., et al.: Targeting HER2-po sitive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res, 2008, 68, s. 9280–9290. 11 Beeram, M. – Burris, H. A. – Modi, S. – Birkner, M. – Girish, S. – Tibbitts, J.: A phase I study of trastuzumab-DM1 (T-DM1), a fi rst in class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC). Proc Am Soc Clin Oncol, 2008, 26, abstr. 1028. 12 Krop, I. E. – Mita, M. – Burris, H. A., et al.: A phase I study of weekly dosing of trastuzumab- DM1 (T-DM1) in patients with advanced HER2+ breast cancer. Prezentováno: 31st Annual San Antonio Breast Cancer Symposium; 10.–14. 12. 2008; San Antonio, TX. Abstrakt 3136. 13 Vogel, C. L. – Burris, H. A. – Limentani, S., et al.: A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): final results. Proc Am Soc Clin Oncol, 2009, 27 (dopl. 15), abstr. 1017. 14 Alvarez, R. H. – Valero, V. – Gabriel, N. – Hortobagyi, G. N.: Emerging Targeted Therapies for Breast Cancer. J Clin Oncol, 2010, 28, s. 3366–3379. 15 Jordan, M. A. – Kamath, K. – Manna, T., et al.: The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther, 2005, 4, s. 1086–1095.

16 Okouneva, T. – Azarenko, O. – Wilson, L., et al.: Inhibition of centromere dynam-ics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther, 2008, 7, s. 2003–2011. 17 Towle, M. J. – Salvato, K. A. – Budrow, J., et al.: In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res, 2001, 61, s. 1013–1021. 18 Goel, S. – Mita, A. C. – Mita, M., et al.: A Phase I study of eribulin mesy late (E7389), a mechanistically novel inhibitor of microtubule dyna mics, in patients with advanced solid tumors. Clin Cancer Res, 2009, 15, s. 4207–4212. 19 Tan, A. R. – Rubin, E. H. – Walton, D. C., et al.: Phase I study of eribulin mesylate (E7389) administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res, 2009, 15, s. 4213–4218. 20 Vahdat, L. T. – Pruitt, B. – Fabian, C. J., et al.: Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol, 2009, 27, s. 2954–2961. 21 Cortes, J. – Vahdat, L. – Blum, J. L., et al.: Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol, 2010, 28, s. 3922–3928. 22 Iwata, H. – Aogi, K. – Masuda, N., et al.: Efficacy and safety of eribulin in Japanese patients (pts) with advanced breast cancer. J Clin Oncol, 2010, 28, s. 1081. 23 Twelves, C. – Loesch, D. – Blum, J. L., et al.: A phase III study(EMBRACE) of eribulin mesylate versus treatment of physician’s choice in patients with locally recurrent or metastatic breast cancer previously trea ted with an anthracycline and a taxane. J Clin Oncol, 2010, 28, abstr. CRA1004. 24 Cigler, T. – Vyndat, L.: Eribulin mesylate for the treatment of breast cancer. Expert Opin. Pharmacother, 2010, 11 (9), s. 1587–1593. 25 Cortes, J. – O’Shaughnessy, J. – Losech, D., et al.: Eribulin monothe rapy versus treatment of physician’s choice in patients with metasta tic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet, 2011, 377, s. 914–923. 26 Hortobagyi, G. N.: Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial. 2011 San Antonio Breast Cancer Symposium. Updated late breaking abstract No. S3-7, 7. 12. 2011. 27 Dawood, S. – Broglio, K. – Giordano, S. H., et al.: Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol, 2010, 28 (1), s. 92–98.


Projekt 35 – příliš mladá na karcinom prsu? doc. MUDr. Petra Tesařová, DrSc. Onkologická klinika 1. LF UK a VFN, Praha 1 Parkin, D. M.: Cancers attributable to exposure to hormones in the UK in 2010. Br J Cancer, 2011, 105 (S2), s. S42–S48. 2 Sidoni, A. – Cavaliere, A. – Bellezza, G. – Scheibel, M. – Bucciarelli, E.: Breast cancer in young women: :clinicopathological features and biological specificity. Breast, 2003, 12 (4), s. 247–250. 3 Ménard, S. – Casalini, P. – Cascinelli, N. – Balsari, A.: Breast carcinoma in young patients. Lancet, 2000, 356 (9235), s. 1113, 1123. 4 Jmor, S. – Al-Sayer, H. – Heys, S. D. – Payne, S. – Miller, I. – Ah-See, A. – Hutcheon, A. – Eremin, O.: Breast cancer in women aged 35 and under: prognosis and survival. J R Coll Surg Edinb, 2002, 47 (5), s. 693–699.

5 Hartmann, S. – Reimer, T. – Gerber, B.: Management of early invasive breast cancer in very young women (<35 years). Clin Breast Cancer, 2011, 11 (4), s. 196–203. 6 Francis, P. A.: Optimal adjuvant therapy for very young breast cancer patients. Breast, 2011, 20 (4), s. 297–302. 7 de Bree, E. – Makrigiannakis, A. – Askoxylakis, J. – Melissas, J. – Tsiftsis, D. D.: Pregnancy after breast cancer. A comprehensive review. J Surg Oncol, 2010, 101 (6), s. 534–542. 8 Hulvat, M. C. – Jeruss, J. S.: Maintaining fertility in young women with breast cancer. Curr Treat Options Oncol, 2009, 10 (5–6), s. 308–317.

Nejnovější poznatky v léčbě pokročilého hepatocelulárního karcinomu prof. MUDr. Jitka Abrahámová, DrSc. Onkologická klinika 1. LF UK a Thomayerovy nemocnice s poliklinikou, KOC (NNB, VFN a TN), Praha 1 Chen, C. J. – Liang, K. Y. – Chang A. S., et al.: Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. Hepatology, 1991, 13, s. 398–406. 2 Fattovich, G. – Ribero, M. L. – Pantalena, M., et al.: Hepatitis C virus genotypes: distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe. J Viral Hepat, 2001, 8, s. 206–216. 3 Wilhelm, S. – Carter, C. – Lynch, M., et al.: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov, 2006, 5, s. 835–844. 4 Llovet, J. M. – Bruix, J.: Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol, 2008, 48 (dopl. 1): s. S20–S37. 5 Llovet, J. M. – Bruix, J.: Molecular targeted therapies in hepatocellular carcinoma. Hepatology, 2008, 48, s. 1312–1327. 6 Cheng, A. L. – Kang, Y. K. – Chen, Z., et al.: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo

controlled trial. Lancet Oncol, 2009, 10, s. 25–34. 7 Česká onkologická společnost ČLS JEP. Zásady cytostatické léčby onkologických onemocnění 2011. Dostupné z http://www.linkos.cz/ informace-pro-praxi/zasady-cytostaticke-lecby/ [cit. 4. 5. 2012]. 8 Yoon, S. K. – Ye, S. L. – Marrero, J., et al.: GIDEON (Global Investigation of therapeutic DEcision in Hepatocellular Carcinoma and Of its treatment with sorafeNib) interim results: regional subgroup analysis. Hepatol Int, 2011, 5, 3–558, FC02–05. 9 Abrahámová, J.: Postavení sorafenibu v současné medikamentózní léčbě hepatocelulárního karcinomu. In: Farmakoterapie – Léčba hepa tocelulárního karcinomu 2011, 2011, 7 (speciální příloha), s. 32–39. 10 Kupec, M. – Büchler, T. – Abrahámová, J.: Dlouhodobé přežití pacienta s pokročilým hepatocelulárním karcinomem léčeného sorafenibem. In: Farmakoterapie – Léčba hepatocelulárního karcinomu 2011, 2011, 7 (speciální příloha), s. 40–41. 11 American Society of Clinical Oncology 2012 Gastrointestinal Cancers Sym posium, 19.–21. leden 2012, San Francisco, Kalifornie.

Biologická léčba nádorů ledvin doc. MUDr. Jindřich Fínek, Ph.D. Onkologické a radioterapeutické oddělení FN a LF UK, Plzeň 1 Escudier, B. – Pluzanska, A. – Koralewski, P., et al.: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. AVOREN Trial investigators. Lancet, 2007,370 (9605), s. 2103–2111. 2 Rini, B. I. – Halabi, S. – Rosenberg, J. E., et al.: Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: fi nal results of CALGB 90206. J Clin Oncol, 2010, 28 (13), s. 2137–2143. 3 Motzer, R. J. – Michaelson, M. D. – Redman, B. G., et al.: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol, 2006, 24 (1), s. 16–24. 4 Motzer, R. J. – Rini, B. I. – Bukowski, R. M., et al.: Sunitinib in patients with metastatic renal cell carcinoma. JAMA, 2006, 295 (21),

s. 2516–2524. 5 Motzer, R. J. – Hutson, T. E. – Tomczak, P., et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 2007, 356 (2), s. 115–124. 6 Motzer, R. J. – Hutson, T. E. – Tomczak, P., et al.: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol, 2009, 27 (22), s. 3584–3590. 7 Hudes, G. – Carducci, M. – Tomczak, P., et al.: Temsirolimus, interfe ron alfa, or both for advanced renal-cell carcinoma. Global ARCC Trial. N Engl J Med, 2007, 356 (22), s. 2271–2281. 8 Sternberg, C. N. – Davis, I. D. – Mardiak, J., et al.: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol, 2010, 28 (6), s. 1061–1068, e-pub 25. 1. 2010.


9 Escudier, B.. – Eisen, T. – Stadler, W. M., et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. TARGET Study Group. N Engl J Med, 2007, s. 356 (2), s. 125–134. 10 Escudier, B. – Szczylik, C. – Hutson, T. E.: Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol, 2009, 27 (8), s. 1280–1289, e-pub 26. 1. 2009. Erratum in: J Clin Oncol, 2009, 27 (13), s. 2305. 11 Stadler, W. M. – Figlin, R. A. – McDermott, D. F., et al.: ARCCS Study Investigators. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer, 2010, 116 (5), s. 1272–1280. 12 Beck, J. – Bajetta, E. – Escudier, B., et al.: A large open-label, non-comparative, phase III study of the multi-targeted kinase inhibitor Sorafenib in European patients with advanced renal cell carcinoma. European Journal of Cancer Suppl, 2007, 5, 300 s. 4506.

13 Motzer, R. J. – Escudier, B. – Oudard, S., et al.: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. RECORD-1 Study Group. Lancet, 2008, 372 (9637), s. 449–456. 14 SPC Votrient, červen 2010. 15 CHMP assessment report/Votrient,14. 6. 2010, www.ema.europa.eu. 16 Sternberg, C. N. – Davis, I. D. – Mardiak, J., et al.: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J Clin Oncol, 2010, 28, s. 1061–1068. 17 Sternberg, C. N. – Szczylik, C. – Lee, E., et al.: A randomized, doubleblind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). Presentation at the 45th Annual Meeting American Society of Clinical Oncology, Orlando, Florida, 29. 5.–2. 6. 2009. 18 Hutson, T. E., et al.: Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol, 2010, 28 (3), s. 475–480.

Karcinom plic MUDr. Bohdan Kadlec | prof. MUDr. Jana Skřičková, CSc. | MUDr. Marcela Tomíšková Klinika nemocí plicních a tuberkulózy LF MU a FN, Brno 1 Adam, Z., et al.: Systémové a paraneoplastické projevy maligních onemocnění. Vnitř Lék, 2007, 53 (3), s. 253–285. 2 Demedts, I. K. – Vermaelen, K. Y. – van Meerbeeck, J. P.: Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J, 2010, 35, s. 202–215. 3 Gao, G. – Ren, S. – Li, A. – Xu, J. – Xu, Q. – Su, C. – Guo, J. – Deng, Q. – Zhou, C.: Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-linetreatment of advanced non-small-cell lung cancer with mutated EGFR: Ameta-analysis from six phase III randomized controlled trials. Int J Cancer, 2011, doi: 10.1002/ijc.27396. 4 Goldstraw, P. – Crowley, J. – Chansky, K. – Giroux, D. J. – Groome, P. A., et al.: The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol, 2007, 2, s. 706–714. 5 Goldstraw, P. – Crowley, J. J.: The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer. J Thorac Oncol, 2006, 1, s. 281–286. 6 Hansen, M.: Paraneoplastic syndromes and tumor markers for small-cell and non-small-cell lung cancer. Curr Opin Oncol, 1990, 2, s. 345–351. 7 Johnson, B. E. – Janne, P. A.: Basic treatment considerations using chemotherapy for patients with small cell lung cancer. Hematol Oncol Clin North Am, 2004, 18, s. 309–322. 8 Molina, J. R. – Dusi, A. A. – Jett, J. R.: Advances in Chemotherapy of Non-small Cell Lung Cancer. CHEST, 2006, 130, s. 1211–1219. 9 Murray, N. – Turrisi, A. T.: A review of first-line treatment for small-cell lung cancer. J Thorac Oncol, 2006, 1, s. 270–278. 10 NSCLC Meta-Analyses Collaborative Group: Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non-Small- Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled Trials. J Clin Oncol, 2008, 26, s. 4617–4625. 11 Patel, S. – Macdonald, O. K. – Suntharalingam, M.: Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer. Cancer, 2009, 115, s. 842–850. 12 Pešek, M., et al.: Bronchogenní karcinom. Praha, Galén, 2002. 13 Pešek, M. – Skřičková, J. – Kolek, V. – Zatloukal, P. – Petruželka, L. – Tomíšková, M. – Krákorová, G. – Grygárková, I. – Havel, P. – Zemanová, M. – Minárik, M. – Svobodník, A. – Dušek, L. – Chroust,

K. – Kaisarová, P. – Šlégrová, Z. – Berkovcová, J. – Hajdúch, M.: Výsledky klinického hodnocení účinnosti a toxicity gefitinibu v rámci programu časného přístupu u nemalobuněčného karcinomu plic v České republice. Studia Pneumologica et Phthiseologica, 2009, 69, 2, s. 61–68. 14 Pijls-Johannesma, M. – De Ruysscher, D. – Vansteenkiste, J., et al.: Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Cancer Treat Rev, 2007, 33, s. 461–473. 15 Reck, M. – von Pawel, J. – Zatloukal P., et al.: Phase III trial of cispla tin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol, 2009, 27 (14), s. 2415. 16 Rosell, R. – Carcereny, E. – Gervais, R. – Vergnenegre, A. – Massuti, B. – Felip, E., et al.: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-posi tive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 2012, 13, s. 239–246. 17 Scott, W. J. – Howington, J. – Feigenberg, S., et al.: Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest, 2007, 132, s. 234S. 18 Sculier, J. – Pand Moro-Sibilot, D.: First-and second-line therapy for advanced nonsmall cell lung cancer. Eur Respir J, 2009, 33, s. 915–930. 19 Secretan, B. – Straif, K. – Baan, R., et al.: A review of human carcinogens-Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol, 2009, 10, s. 1033–1034. 20 Shepherd, F. A. – Crowley, J. – van Houtte, P. – Postmus, P. E. – Carney, D., et al.: The International Association for the Study of Lung Cancer lung cancer staging project:proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol, 2007, 2, s. 1067–1077. 21 Shepherd, F. A. – Evans, W. K. – Feld, R., et al.: Adjuvant chemothera py following surgical resection for small-cell carcinoma of the lung. J Clin Oncol, 1988, 6, s. 832–838. 22 Schneider, B. J.: Management of recurrent small cell lung cancer. J Natl Compr Canc Netw, 2008, 6, s. 323–331. 23 Simon, M. – Argiris, A. – Murren, J. R.: Progress in the therapy of small cell lung cancer. Crit Rev Oncol Hematol, 2004, 49, s. 119–133. 24 Skřičková, J., et al.: Bronchogenní karcinom (41–62). In: Adam, Z. – Vorlíček, J. – Vaníček, J., et al.: Diagnostické a léčebné postupy u maligních


chorob. Grada Publishing, Praha, 2004. 25 Yu, J. B. – Decker, R. H. – Detterbeck, F. C. – Wilson, L. D.: Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer. J Thorac Oncol, 2010, 5, s. 215–219. 26 Zatloukal, P. – Petruželka, L.: Karcinom plic. Praha, Grada, 2001.

27 Zhou, C. – Wu, Y. L. – Chen, G. – Feng, J. – Liu, X. Q. – Wang, C., et al.: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011, 12, s. 735–742.

Komplexní léčba metastatického kolorektálního karcinomu MUDr. Igor Kiss, Ph.D. | MUDr. Jana Halámková Klinika komplexní onkologické péče MOU a LF, Brno 1 Software pro vizualizaci onkologických dat (SVOD), www.svod.cz. 2 Screening kolorektálního karcinomu, www.kolorektum.cz. 3 Van Cutsen, E. – Kohne, C. H. – Hitre, E., et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med, 2009, 360, s. 1408–1417. 4 Hurwitz, H. – Fehrenbacher, L. – Novotny, W., et al.: N Engl J Med, 2004, 350, s. 2335–2342. 5 Saltz, L. B. – Clarke, S. – Díaz-Rubio, E., et al.: Bevacizumab in combination with oxaliplatin based chemotherapy as first line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol, 2008, 26, s. 2013–2019. 6 Bismuth, H. – Adam, R. – Levi F., et al.: Resection of nonresectable liber metastase from colorectal cancer after neoadjuvant chemotherapy.

Ann Surg, 1996, 224, s. 509–522. 7 Adam, R. – Wicherts, D. A. – de Haas, R. J., et al.: Patient wit initially unresectable colorectal liver metastase : is there a posibility of cure? J Clin Oncol, 2009, 27, s. 1829–1835. 8 Nordlinger, B. – Skrbte, H. – Glimelius, B., et al.: Preoperative chemotherapy whith FOLFOX4 and surgery versus surgery alone for resectab le liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial. Lancet, 2008, 371, s. 1007–1016. 9 Kubala, E. – Bartoš, J. – Petrželka, L., et al.: Safety and effectivness of bevacizumab in combination with chemotherapy in patients with metastatic colorectal cancer in eldery population:updated results from a large Czech observational registry. ASCO GI, 2010.

Karcinom žaludku MUDr. Jiří Tomášek Klinika komplexní onkologické péče MOU, Brno 1 Cunningham, D. – Allum, W. H. – Stenning, S. P., et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 2006, 355, s. 11–20. 2 Macdonald, J. S. – Smalley, S. R. – Benedetti, J., et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med, 2001, 345, s. 725–730. 3 Wagner, A. D. – Grothe, W. – Haerting, J., et al.: Chemotherapy in ad vanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol, 2006, 24, s. 2903–2909. 4 Cunningham, D. – Starling, N. – Rao, S., et al.: Capecitabine and oxa liplatin for advanced esophagogastric cancer. N Engl J Med, 2008, 358 (1), s. 36–46. 5 Van Cutsen, E. – Moiseyenko, V. M. – Tjulandin, S., et al.: Phase III stu dy of docetaxel and cisplatin plus fluorouracil compared with cisplatin

and fluorouracil as first-line therapy for advanced gastric cancer: a Report of the V325 Study Group. J Clin Oncol, 2006, 24, s. 4991–4997. 6 Ajani, J. A. – Moiseyenko, V. M. – Tjulandin, S., et al.: Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a Phase III trial for advanced gastric or gastroeso phageal adenocarcinoma: The V-325 Study Group. J Clin Oncol, 2007, 25, s. 3210–3216. 7 Moehler, M. – Eimermacher, A. – Siebler, J., et al.: Randomized Phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) versus 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer, 2005, 92, s. 2122–2128. 8 Van Cutsem, E. – Kang, Y. – Chung, H., et al.: Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy in firstline human epidermal growth factor receptor 2-positive advanced gastric cancer. J Clin Oncol, 2009, 27 (15S), LBA4509.

Germinální nádory varlat – přehled diagnostiky a terapie MUDr. Tomáš Büchler, Ph.D. | prof. MUDr. Jitka Abrahámová, DrSc. Onkologická klinika Fakultní Thomayerovy nemocnice s poliklinikou a 1. LF UK, Praha 1 Dušek, L. – Mužík, J. – Kubásek, M., et al.: Epidemiologie zhoubných nádorů v České republice. Masarykova univerzita, 2005, cit. 4. 10. 2012, http://www.svod.cz. 2 McGlynn, K. A. – Cook, M. B.: Etiologic factors in testicular germ-cell tumors. Future Oncol, 2009, 5 (9), s. 1389–1402. 3 International Germ Cell Cancer Collaborative Group: Internatio nal Germ Cell Consensus Classification: a prognostic factor-based

staging system for metastatic germ cell cancers. J Clin Oncol, 1997, 15, s. 594–603. 4 Capelouto, C. C. – Clark, P. E. – Ransil, B. J., et al.: A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary? J Urol, 1995, 153, s. 981–985. 5 Abrahámová J.: Léčebné postupy u nepokročilých testikulárních ger minálních nádorů neseminomového typu. Klinická onkologie, 2008, 21,


3, s. 81–85. 6 Abrahámová J.: Radioterapie germinálních nádorů. In: Abrahámová, J. – Dušek, L. – Povýšil, C., et al.: Nádory varlat, Grada, 2008, s. 195–205. 7 Krege, S. – Beyer, J. – Souchon. R. – et al.: European consensus confe rence on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol, 2008, 53 (3), s. 497–513. 8 Kondagunta, G. V. – Bacik, J. – Donadio, A., et al.: Combination of pa clitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol, 2005,

23 (27), s. 6549–6555. 9 Einhorn, L. H. – Williams, S. D. – Chamness, A., et al.: High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med, 2007, 357 (4), s. 340–348. 10 Fossa, S. D. – Bokemeyer, C. – Gerl, A., et al.: Treatment outcome of patients with brain metastases from malignant germ cell tumors. Cancer, 1999, 85, s. 988–997. 11 Buchler, T. – Kubankova, P. – Boublikova, L., et al.: Detection of se cond malignancies during long-term follow-up of testicular cancer survivors. Cancer, 2011, 117, s. 4212–4218.

Současné možnosti léčby karcinomu slinivky břišní MUDr. Michal Vočka | prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika 1. LF UK a VFN a ÚVN, Praha 1 Hidalgo, M.: Pancreatic Cancer. N Engl J Med, 2010, 362, s. 1605–1617. 2 Verdecchia, A. – Francisci, S. – Kunkler, I., et al.: Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncology, 2007, 8 (9), s. 784–796. 3 Roazzi, P. – Capocaccia, R. – Santaquilani, M. – Carrani, E.: Electronic availability of EUROCARE-3 data: a tool for further analysis. Ann Oncol, 2003, 14 (dopl. 5), s. 150–155. 4 www.svod.cz. 5 Dušek, L., et al.: Czech Cancer Care in Numbers 2008–2009. Grada Publishing, Praha, 2009. 6 Hanash, S. M., et al.: Emerging molecular biomarkers-blood-based strategies to detect and monitor cancer. Nat. Rev. Clin. Oncol, 2011, 8, s. 142–150. 7 Abramson, M. A. – Jazag, A. – van der Zee, J. A. – Whang, E. E.: The Molecular Biology of Pancreatic Cancer. Gastrointest Cancer Res, 2007, 1, s. 7–12. 8 Cascinu, S. – Falconi, M. – Valentini, V. – Jelic, S.: On behalf of the ESMO Guidelines Working Group: Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2010, 21, s. 55–58. 9 Chang, D. K. – Johns, A. L., et al.: Margin Clearance and Outcome in Resected Pancreatic Cancer. J Clin Oncol, 2010, 27, s. 2855–2862. 10 Balcom, J. H. – Rattner, D. W. – Warshaw, A. L. – Chang, Y. – Fernandez-del, C. C.: Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. Arch Surg, 2001, 136, s. 391–398. 11 Birkmeyer, J. D. – Finlayson, S. R. – Tosteson, A. N. – Sharp, S. M. – Warshaw, A. L. – Fisher, E. S.: Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. Surgery, 1999, 125, s. 250–256. 12 Stocken, D. D. – Buchler, M. W. – Dervenis, C. – Bassi, C. – Jeekel, H. – Klinkenbijl, J. H., et al.: Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer, 2005, 92, s. 1372–1381. 13 GITSG. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer, 1987, 59, s. 2006–2010. 14 Klinkenbijl, J. H. – Jeekel, J. – Sahmoud, T. – van Pel, R. – Couvreur, M. L. – Veenhof, C. H., et al.: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer coope rative group. Ann Surg, 1999, 230, s. 776–782. 15 Neoptolemos, J. P. – Dunn, J. A. – Stocken, D. D. – Almond, J. – Link, K. – Beger, H., et al.: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet, 2001, 358, s. 1576–1585. 16 Regine, W. F. – Winter, K. W. – Abrams, R. – Safran, H. – Hoffman,

J. P. – Konski, A., et al.: RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. J Clin Oncol, 2006, 24, No. 18S: 4007. 17 Ben-Josef, E. – Lawrence, T. S.: The importance of local kontrol in pancreatic cancer. Clin Oncol, 2012, 9, s. 9–10. 18 Stathis, A. – Moore, M. J.: Advanced pancreatic carcinoma: current treatment and future challenges. Nat. Rev. Clin. Oncol, 7, 2010, s. 163–172. 19 Huguet, F. – Girard, N. – Guerche, C. S. – Hennequin, C. – Mornex, F. – Azria, D.: Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol, 2009, 27, s. 2269–2277. 20 Heinemann, V. – Boeck, S. – Hinke, A. – Labianca, R. – Louvet, C.: Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer, 2008, 8, s. 82–85. 21 Conroy, T., et al.: FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Eng J Med, 2011, 364, s. 1817–1825. 22 Tempero, M. A., et al.: Pancreatic cancer treatment and research: an international expert panel discussion. Ann Oncol, 2011, s. 93–99. 23 Philip, P., et al.: Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or meta static pancreatic adenocarcinoma [PC]: SWOG S0205 study. J Clin Oncol, 2007, 25, s. a4509. 24 Van Cutsem, E. – Vervenne, W. – Bennouna, J., et al.: Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreaticcancer. J Clin Oncol, 2008, 27, s. 2231–2237. 25 Kindler, H. L. – Priberg, G. – Singh, D. A., et al.: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol, 2005, 23, s. 8033–8040. 26 Van Cutsem, E. – van de Velde, H. – Karasek, P., et al.: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol, 2004, 22, s. 1430–1438. 27 Moore, M. J., et al.: Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 2007, 25, s. 1960–1966. 28 Pelzer, U. – Stieler, J., et al.: A randomised second line trial in patients with gemcitabine refractory advanced pancreatic cancer- CONKO 003. J Clin Onco, 2007, 25 (dopl.), s. 201. 29 Harsha, H. C. – Kandasamy, K. – Ranganathan, P., et al.: A compendium of potential biomarkers of pancreatic cancer. PLoS Med, 2009, 6 (4), s. e1000046. 30 Burris, H. A., et al.: J Clin Oncol, 1997, 15, s. 2403–2413. 31 Conroy, T., et al.: ASCO, 2010, abstrakt 4010.


Výživa onkologického pacienta doc. MUDr. Miroslav Tomíška, CSc. Interní hematologická a onkologická klinika LF MU a FN, Brno 1 Andreyev, H. J. N. – Norman, A. R. – Oates, J. – Cunningham, D.: Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer, 1998, 34, s. 503–509. 2 Awad, S. – Tan, B. J. – Cui, H., et al.: Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin Nutrition, 2012, 31, s. 74–77. 3 Barber, M. D. – Ross, J. A. – Fearon, K. C. H.: Cancer cachexia. Surg Oncol, 1999, 8, s. 133–141. 4 Braga, M. – Gianotti, L. – Radaelli, G., et al.: Perioperative immunonutrition in patients undergoing cancer surgery: results of a randomized doube-blind phase 3 trial. Arch Surg, 1999, 134 (4), s. 428–433. 5 Camps, C. – Iranzo, V. – Bremnes, R. M. – Sirera, R.: Anorexia-cachexia syndrome in cancer: implications of the ubiquitin-proteasome pathway. Supp Care Cancer, 2006, 14, s. 1173–1183. 6 Davidson, W. – Ash, S. – Capra, S., et al.: Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer. Clin Nutrition, 2004, 23, s. 239–247. 7 Fearon, K. C. H. – Barber, M. D. – Moses, A. G., et al.: Double-blind, placebo controlled, randomised study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol, 2006, 24, s. 3401–3407. 8 Hoda, D. – Jatoi, A. – Burnes, J., et al.: Should patients with advanced, incurable cancers ever be sent home with total parenteral nutrition? A singles institution´s 20-years experience. Cancer, 2005, 103, s. 863–868. 9 Khalid, U. – Spiro, A. – Baldwin, C., et al.: Symptoms and weight loss

in patients with gastrointestinal and lung cancer at presentation. Sup por Care Cancer, 2007, 15, s. 39–46. 10 McMillan, D. C. – Watson, W. S. – Preston, T. – McArdle, C. S.: Lean body mass changes in cancer patients with weight loss. Clinical Nutri tion, 2000, 19, s. 403–406. 11 Moses, A. W. G. – Slater, C. – Preston, T., et al.: Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer, 2004, 90, s. 996–1002. 12 Nitenberg, G. – Raynard, B.: Nutritional support of the cancer patient: issues and dilemmas. Critical Review in Oncology/Hematology, 2000, 34, s. 137–168. 13 Ovesen, L. – Allingstrup, L. – Hannibal, J. – Mortensen, E. L. – Hansen, O. P.: Effect of dietary counselling on food intake, body weight, res ponse rate, survival, and quality of life in cancer patients undergoing chemotherapy: A prospective, randomized study. J Clin Oncol, 1993, 11, s. 2043–2049. 14 Ravasco, P. – Monteiro-Grillo, I. – Vidal, P. M., et al.: Dietary counselling improves patient outcomes: a prospective, randomized controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin On cology, 2005, 23, s. 1431–1438. 15 Tisdale, M. J.: Cachexia in cancer patients. Nature Reviews, 2002, 2, s. 862–871. 16 Zadák, Z.: Enterální výživa u pacientů s nádorovým onemocněním. In: Wilhelm, Z., et al.: Výživa v onkologii. Institut pro další vzdělávání pracovníků ve zdravotnictví, Brno, 2001.

Současné možnosti léčby průlomové bolesti onkologických pacientů MUDr. Ondřej Sláma, Ph.D. Ambulance podpůrné a paliativní onkologie, Klinika komplexní onkologické péče MOU, Brno 1 Davies, A. M. – Dickman, A. – Reid, C., et al.: The management of cancer-related breakthrough pain: Recommendations of a taskgroup of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. European Journal of Pain, 2009, 13, s. 331–338. 2 Haugen, D. F. – Hjermstad, M. J. – Hagen, N., et al.: Assessment and classification of cancer breakthrough pain: A systematic literature review. Pain, 2010, 149, s. 476–482. 3 Kabelka, L. – Lejčko, J. – Kozák, J. – Sláma, O.: Doporučený postup pro léčbu průlomové nádorové bolesti. Farmakoterapie, 2011, 7 (5), s. 521–523.

4 Portenoy, R. K. – Forbes, K. – Lussier, D. – Hanks, G.: Difficult pain problems: an integrated approach. In: Doyle, D. – Hanks, G. – Cherny, N. – Calman, K. (eds.): Oxford textbook of palliative medicine. Oxford, Oxford University Press, 2004, s. 438–458. 5 Sláma, O. – Lejčko, J. – Kozák, J., et al.: Epidemiologie a léčba průlo mové bolesti u onkologických pacientů v ČR. Výsledky výzkumného projektu PARMA. Část 1. Prevalence a klinické charakteristiky průlomo vé bolesti. Bolest, 2011, 14 (1), s. 158–160. 6 Mercadante, S. – Villari, P. – Ferrera, P. – Casuccio, A.: Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Sympt Manage, 2004, 28, s. 505–510.


Léčba olanzapinem u pacientů se schizofrenií doc. MUDr. Klára Látalová, Ph.D. Klinika psychiatrie FN Olomouc, LF UP, Olomouc 1 Breier, A. – Meehan, K. – Birkett, M., et al.: A double-blind, placebocontrolled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry, 2002, 59, s. 441–448. 2 Hill, A. L. – Sun, B. – Karagianis, J. L., et al.: Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia. BMC Psychiatry, 2011, 15, s. 11–28. 3 Kane, J. M. – Detke, H. C. – Naber, D., et al.: Olanzapine long-acting injection: A 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry, 2010, 167, s. 181–189. 4 Komossa, K. – Rummel-Kluge, C. – Hunger, H., et al.: Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev, 2010, 3, CD006654. 5 Lauriello, J. – Lambert, T. – Andersen, S., et al.: An 8-week, double blind, randomized, placebo-controlled study of olanzapine long-actinginjection in acutely ill patients with schizophrenia. J Clin Psy chiatry, 2008, 69, s. 790–799.

6 Leucht, S. – Komossa, K. – Rummel-Kluge, C., et al.: A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry, 2009, 166, s. 152–163. 7 Lieberman, J. A. – Stroup, T. S. – McEvoy, J. P., et al.: Effectiveness of antipsychotic drugs in patiens with chronic schizophrenia. N Engl J Med, 2005, 353, s. 1209–1223. 8 Meehan, K. – Zhang, F. – David, S. – Tohen, M., et al.: A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol, 2001, 21, s. 389–397. 9 Meehan, K. M. – Wang, H. – David, S. R. – Nisivoccia, J. R., et al.: Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology, 2002, 26, s. 494–504. 10 Wright, P. – Birkett, M. – David, S. R., et al.: Double-blind, placebocontrolled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry, 2001, 158, s. 1149–1151.

Depresivní porucha a její léčba prof. MUDr. Ján Praško, CSc. | doc. MUDr. Klára Látalová, Ph.D. Klinika psychiatrie FN Olomouc, LF UP, Olomouc 1 American Psychiatric Association: Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psy chiatry, 2000, 157 (dopl.), s. 1–45. 2 Bauer, M. – Bschor, T. – Kuntz, D. – Berhöfer, A. – Stöhle, A. – Müller-Oerlinghausen, B.: Double blind, placebo controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry, 2000, 157, s. 1429–1435. 3 Beck, A. T. – Rush, A. J. – Shaw, B. F. – Emery, G.: Cognitive Therapy of Depression. New York, Guilford, 1979. 4 Clinical Guidelines for The Treatment of Depressive Disorders (Clinical Practice Guidelines). The Canadian Journal of Psychiatry, 2001, 46 (dopl. 1), s. 91. 5 Crismon, M. L. – Trivedi, M. – Pigott, T. A. – Rush, A. J. – Hirschfeld, R. M. – Kahn, D. A. – De Battista, C. – Nelson, J. C. – Nierenberg, A. A. – Sackeim, H. A. – Thase, M. E.: The Texas Algorithm Project: report of the Texas Consensus Conference Panel on medication treatment of major depressive disorder. J Clin Psychiatry, 1999, 60, s. 142–156. 6 El-khalili, N. – Joyce, M. – Atkinson, S.: Adjunctive extended-release quetiapine fumarate in patients with major depressive disorder and ina dequate antidepressant response. 16st Annual Meeting of the American Psychiatrie Association, Washington DC, USA, 2008. 7 Frank, E. – Prien, R. F. – Jarrett, R. B. – Keller, M. B. – Kupfer, D. J. – Lavori, P. W. – Rush, A. J. – Weissmann, M. M.: Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Arch Gen Psychiatry, 1991, 48, s. 851–855. 8 Geddes, J. R. – McCarney, S. M. – Davies, C. – Furukawa, T. A. – Kupfer, D. J. – Goodwin, G. M.: Relapse prevention with antidepressant drug treatment in depressive disorder: a systematic review. Lancet, 2003, 361, s. 653–661. 9 Kessler, R. C. – Berglund, P. – Demler, O., et al.: The epidemiology of major depressive disorder: results from the National Comorbidity

Survey Replication (NCS-R). JAMA, 2003, 289, s. 3095–3105. 10 McPherson, S. – Cairns, P. – Carlyle, J. – Shapiro, D. A. – Richardson, P. – Taylor, D.: The effectiveness of psychological treatments for treatment-resistant depression: a systematic review. Acta Psychiatr Scand, 2005, 111 (5), s. 331–340. 11 Mezinárodní klasifikace nemocí. 10. revize. Duševní poruchy a poruchy chování: Popisy klinických příznaků a diagnostická vodítka (přeloženo z anglického originálu). Praha, Psychiatrické centrum, 1992, Zprávy č. 102. 12 Montgomery, S. – Cutler, A. – Lazarus, E.: Extended release quetiapine fumarate monotherapy in the treatment of patients with major depressive disorder. 16th European Congress of Psychiatry, Nice, Francie, 2008. 13 Moore, R. G. – Garland, A.: Cognitive Therapy for Chronic and Persistent Depression. Chichester, John Wiley and Sons, 2003. 14 Murray, C. J. – Lopez, A. D.: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet, 1997, 349, s. 1498–1504. 15 Praško, J.: Bright light therapy. Neuroendocrinology Letters, 2008, 29 (dopl. 1), s. 33–64. 16 Quitkin, F. M. – McGrath, J. P. – Stewart, J. W.: Chronological milestones to guide drug change: when should clinician switch antidepressant? Arch Gen Psychiatry, 1996, 53, s. 785–792. 17 Rush, A. J. – Trivedi, M. H. – Wisniewski, S. R. – Nierenberg, A. A. – Stewart, J. W. – Warden, D., et al.: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry, 2006, 163 (11), s. 1905–1917. 18 Segal, Z. – Williams, J. M. – Teasdale, J.: Mindfulness -based cognitive therapy for depression. New York, The Guilford Press, 2002. 19 Thase, M. E. – Friedman, E. S. – Howland, R. H.: Management of treatment-resistant depression: psychotherapeutic perspectives. J Clin Psy chiatry, 2001, 62 (dopl. 18), s. 18–24.


20 Thase, M. E.: Effects of venlafaxine on blood pressure: a metanalysis of original data from 3744 depressed patients. J Clin Psychiatry, 1998, 59, s. 502–508. 21 Thase, M. E.: Relapse and recurrence in unipolar major depression: Short-term and long-term approaches. J Clin Psychiatry, 1990, 5 (dopl.), s. 51–57. 22 Weisler, R. – Joyce, M. – Mc Gill, L.: Extended release quetiapine fumu rate monotherapy for major depressive disorder (MDD): a double-blind

placebo-controlled study. American Psychiatric Association, Washington D. C., USA, 2008. 23 Weissman, M. M. – Leaf, P. J. – Tischler, G. L., et al.: Affective disorders in five United States communities. Psychol Med, 1988, 18, s. 141–153. 24 WHO: WHO Report 2001: Mental Health. New Hope: New Understanding. 2001, kapitola 2: Burden of Mental and Behavioral Disorders. 25 World Health Organization, Mental Health Collaborating Centers, 1989.

Role mikroRNA při vzniku nádorů a možnosti jejich využití v léčbě prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha 1 Lujambio, A. – Lowe, S. W.: The microcosmos of cancer. Nature, 2012, 484, s. 347–355. 2 Calin, G. A. – Dumitru, C. D. – Shimizu, M. – Bichi, R. – Zupo, S. – Noch, E. – Adler, H. – Rattan, S. – Keating, M. – Rai, K. – Rassenti, L. – Kipps, T. – Negrini, M. – Bullrich, F. – Croce, C. M.: Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences, 2002, 99, s. 15524–15529. 3 Lu, J. – Getz, G. – Miska, E. A. – Alvarez-Saavedra, E. – Lamb, J. – Peck, D. – Sweet-Cordero, A. – Ebert, R. L. – Mak, R. H. – Ferrando, A. A. – Downing, J. R. – Jacks, T. – Horvitz, H. R. – Golub, T. R.: MicroRNA expression profiles classify human cancers. Nature, 2005, 435, s. 834–838. 4 Yanaihara, N. – Caplen, N. – Bowman, E. – Seike, M. – Kumamoto, K. – Yi, M. – Stephens, R. M. – Okamoto, A. – Yokota, J. – Tanaka, T. – Calin, G. A. – Liu, C.-G. – Croce, C. M. – Harris, C. C.: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 2006, 9, s. 189–198. 5 Mitchell, P. S. – Parkin, R. K. – Kroh, E. M. – Fritz, B. R. – Wyman, S. K. – Pogosova-Agadjanyan, E. L. – Peterson, A. – Noteboom, J. – O‘Briant, K. C. – Allen, A. – Lin, D. W. – Urban, N. – Drescher, C. W. – Knudsen, B. S. – Stirewalt, D. L. – Gentleman, R. – Vessella, R. L. – Nelson, P. S. – Martin, D. B. – Tewari, M.: Circulating microRNAs as stable bloodbased markers for cancer detection. Proceedings of the National Aca demy of Sciences, 2008, 105, s. 10513–10518. 6 Thomson, J. M. – Newman, M. – Parker, J. S. – Morin-Kensicki, E. M. – Wright, T. – Hammond, S. M.: Extensive post-transcriptional regulation

of microRNAs and its implications for cancer. Genes & Development, 2006, 20, s. 2202–2207. 7 Chang, T.-C. – Yu, D. – Lee, Y.-S. – Wentzel, E. A. – Arking, D. E. – West, K. M. – Dang, C. V. – Thomas-Tikhonenko, A. – Mendell, J. T.: Widespread microRNA repression by Myc contributes to tumorigenesis. Nature Genetics, 2008, 40, s. 43–50. 8 Johnson, S. M. – Grosshans, H. – Shingara, J. – Byrom, M. – Labourier, E. – Reinert, K. L. – Brown, D. – Slack, F. J.: RAS Is regulated by the let-7 MicroRNA Family. Cell, 2005, 120, s. 635–647. 9 He, L. – He, X. – Lowe, S. W. – Hannon, G. J.: microRNAs join the p53 network – another piece in the tumor-suppression puzzle. Nature Reviews Cancer, 2007, 7, s. 819–822. 10 Su, X. – Chakravarti, D. – Cho, M. S. – Liu, L. – Gi, Y. J. – Lin, Y.-L. – Leung, M. L. – El-Naggar, A. – Creighton, C. J. – Suraoka, M. B. – Wistuba, I. – Flores, E. R.: TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature, 2010, 467, s. 986–990. 11 Godlewski, J. – Nowicki, M. O. – Bronisz, A. – Nuovo, G. – Palatini, J. – De Lay, M. – Van Brocklyn, J. – Ostrowski, M. C. – Chiocca, E. A. – Lawler, S. E.: MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Molecular Cell, 2010, 37, s. 620–632. 12 Anand, S. – Majeti, B. K. – Murphy, L. M. – Mukthavaram, R. – Scheppke, L. – Huang, M. – Shields, D. J. – Lindquist, J. N. – Lapinski, P. E. – King, P. D. – Weis, S. M. – Cheresh, D. A.: MicroRNA-132–mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nature Medicine, 2010, 16, s. 909–914.


2012 ONKOLOGIE

Recommend Documents